美國商用葡萄糖生物感測器市場規模、佔有率、趨勢分析報告：按應用、主要企業、競爭分析、細分預測，2025-2030 年

美國OTC葡萄糖生物感測器市場趨勢：

預計 2024 年美國非處方 (OTC) 葡萄糖生物感測器市場規模將達到 1.053 億美元，2025 年至 2030 年複合年成長率為 11.5%。

推動市場成長的因素包括糖尿病和糖尿病前期盛行率不斷上升、預防性醫療保健的轉變以及運動員擴大採用葡萄糖生物感測器等。此外，這個年齡層的人更容易患糖尿病等慢性疾病，從而增加了對葡萄糖生物感測器等有效解決方案的需求。

人口老化、肥胖和不健康的生活方式導致糖尿病盛行率不斷上升，是推動美國非處方（OTC）葡萄糖生物感測器產業成長的因素之一。肥胖是導致糖尿病的一個主要因素。根據哥倫比亞廣播公司 2024 年 9 月發布的新聞報道，到 2020 年，大約 30% 的成年人將被歸類為肥胖，這意味著他們的體重指數 (BMI) 為 30 或更高。此外，疾病預防控制中心報告稱，到 2020 年，成人肥胖率將上升至 41.9%。目前，根據2021-2023年的調查資料，CDC估計40.3%的成年人有肥胖問題。除了肥胖之外，糖尿病在世界各地也變得越來越普遍。國際糖尿病聯盟（IDF）估計，2021年將有5.37億成年人（20-79歲）患有糖尿病，預計2040年將上升到6.42億。 IDF報告也指出，全球糖尿病盛行率呈上升趨勢，中低收入國家的增幅最大。

糖尿病是一個普遍的健康問題，影響著美國數百萬人。據美國疾病管制與預防中心 (CDC) 稱，截至 2024 年，美國人口的 11.6%（各年齡層約 3,840 萬人）將被診斷出患有糖尿病。 18歲以上成年人的盛行率更高，達14.7%，即3810萬人受到影響。大約有 870 萬名患有糖尿病的成年人不知道或未報告自己患有糖尿病，佔糖尿病成年人總數的 22.8%，占美國成年人總數的 3.4%。罹患糖尿病的風險隨著年齡的成長而增加，65歲及以上人口的比例最高，為29.2%。這些統計數據凸顯了糖尿病對美國人口的重大影響。

此外，向預防性醫療保健的轉變也促進了美國非處方（OTC）葡萄糖生物感測器產業的發展。日益增強的認知、政府措施和技術進步正在推動消費者優先考慮健康管理，以避免糖尿病等慢性疾病。預防性醫療保健強調早期檢測和持續監測，這推動了對方便、易於使用的血糖監測設備的需求。

Stelo 和 Lingo 等非處方葡萄糖生物感測器為人們提供了一種方便的、非處方箋的居家血糖值監測選擇。這些設備設計緊湊，易於使用，並提供無縫的智慧型手機整合，以實現即時追蹤和資料分析。 Stelo 和 Lingo 支援主動健康管理，使用戶能夠及早發現血糖水平的變化並及時採取行動，促進預防性糖尿病護理。

目錄

第1章調查方法與範圍

第 2 章執行摘要

第 3美國。

• 市場介紹/電網展望
• 市場規模和成長前景
• 市場動態
  • 市場促進因素分析
  • 市場限制因素分析
• 美國非處方 (OTC) 葡萄糖生物感測器市場分析工具
  • 波特的分析
  • PESTEL 分析

美國4 章。

• 細分儀表板
• 美國非處方 (OTC) 葡萄糖生物感測器市場：最終用途變化分析，2024 年和 2030 年
• 醫療保健專業辦公室 (HCP)
• 專科門診
• 居家護理

第5章 競爭格局

• 主要市場參與企業的近期趨勢及影響分析
• 公司分類
• 公司熱圖分析
• 公司簡介
  • DexCom, Inc.
  • Abbott

U.S. OTC Glucose Biosensors Market Trends:

The U.S. over-the-counter glucose biosensors market size was estimated at USD 105.3 million in 2024 and is anticipated to exhibit a CAGR of 11.5% from 2025 to 2030. This growth is attributed to the increasing prevalence of diabetes and prediabetes, the shift towards preventive healthcare, and the increased adoption of glucose biosensors by athletes are some of the major factors driving market growth. Moreover, the aging population of the country further contributes to this growth as this age group is significantly vulnerable to chronic diseases such as diabetes, which increases the demand for effective solutions such as glucose biosensors.

The increase in the prevalence of diabetes due to aging, obesity, and unhealthy lifestyle is one of the factors contributing to the growth of the U.S. over-the-counter (OTC) glucose biosensors industry. Obesity is a major factor leading to diabetes. According to CBS News published in September 2024, approximately 30% of adults were classified as obese, with a body mass index (BMI) of 30 or higher in 2020. Furthermore, the CDC reported an increase in the adult obesity rate to 41.9% by 2020. Currently, based on survey data from 2021 to 2023, the CDC estimates that 40.3% of adults are obese. In addition to obesity, diabetes is becoming increasingly prevalent globally. The International Diabetes Federation (IDF) estimates that there were 537 million adults (aged 20-79) living with diabetes in 2021, and this number is expected to increase to 642 million by 2040. The IDF also reports that the prevalence of diabetes is growing globally, with the highest increase witnessed in low- and middle-income countries.

In the U.S., diabetes is a widespread health issue affecting millions of people. According to the CDC, as of 2024, 11.6% of the entire U.S. population-about 38.4 million people of all ages-has been diagnosed with diabetes. The percentage of adults aged 18 or older is even higher, with 14.7% or 38.1 million people affected. Around 8.7 million adults with diabetes were unaware of their condition or did not report it, representing 22.8% of all adults with diabetes and 3.4% of all U.S. adults. The risk of diabetes increases with age, with the percentage of adults with diabetes peaking at 29.2% among those aged 65 or above. These statistics highlight the significant impact that diabetes has on the U.S. population.

Moreover, the shift towards preventive healthcare is also contributing to the growth of the U.S. over-the-counter (OTC) glucose biosensors industry. Consumers increasingly prioritize health management to avoid chronic diseases such as diabetes, driven by rising awareness, government initiatives, and technological advancements. Preventive healthcare emphasizes early detection and continuous monitoring, fueling demand for accessible and user-friendly glucose monitoring devices.

OTC glucose biosensors such as Stelo and Lingo provide individuals with convenient, non-prescription options to monitor blood glucose levels at home. These devices offer ease of use with compact designs and seamless smartphone integration for real-time tracking and data analysis. Stelo and Lingo support proactive health management, enabling users to detect early changes in their glucose levels and take timely action, promoting a preventive approach to diabetes care.

U.S. Over-the-Counter Glucose Biosensors Market Report Segmentation

This report forecasts revenue growth at country levels and analyzes the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the U.S. over-the-counter glucose biosensors market report based on end use:

• End-use Outlook (Revenue, USD Million, 2018 - 2030)
• Healthcare Professional Offices (HCPs)
• Specialty Clinics
• Homecare

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Market Definitions
• 1.3. Research Methodology
  • 1.3.1. Information Procurement
  • 1.3.2. Information or Data Analysis
  • 1.3.3. Market Formulation & Data Visualization
  • 1.3.4. Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. U.S. Over the Counter (OTC) glucose biosensors Market Variables, Trends, & Scope

• 3.1. Market Introduction/Lineage Outlook
• 3.2. Market Size and Growth Prospects (USD Million)
• 3.3. Market Dynamics
  • 3.3.1. Market Drivers Analysis
    • 3.3.1.1. Increasing prevalence of diabetes and prediabetes
    • 3.3.1.2. Shift towards preventive healthcare
    • 3.3.1.3. Increased adoption of glucose biosensors by athletes
  • 3.3.2. Market Restraints Analysis
    • 3.3.2.1. Lack of coverage under insurance plans
    • 3.3.2.2. Limitations in OTC biosensors functionality
    • 3.3.2.3. Regulatory challenges
• 3.4. U.S. Over-the-Counter (OTC) Glucose Biosensors Market Analysis Tools
  • 3.4.1. Porter's Analysis
    • 3.4.1.1. Bargaining power of the suppliers
    • 3.4.1.2. Bargaining power of the buyers
    • 3.4.1.3. Threats of substitution
    • 3.4.1.4. Threats from new entrants
    • 3.4.1.5. Competitive rivalry
  • 3.4.2. PESTEL Analysis
    • 3.4.2.1. Political landscape
    • 3.4.2.2. Economic and Social landscape
    • 3.4.2.3. Technological landscape
    • 3.4.2.4. Environmental landscape
    • 3.4.2.5. Legal landscape

Chapter 4. U.S. Over-the-Counter (OTC) Glucose Biosensors Market: End Use Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. U.S. Over-the-Counter (OTC) Glucose Biosensors Market: End Use Movement Analysis, USD Million, 2024 & 2030
• 4.3. Healthcare Professional Offices (HCPs)
  • 4.3.1. Healthcare Professional Offices (HCPs) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.4. Specialty Clinics
  • 4.4.1. Specialty Clinics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.5. Homecare
  • 4.5.1. Homecare Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Competitive Landscape

• 5.1. Recent Developments & Impact Analysis by Key Market Participants
• 5.2. Company Categorization
• 5.3. Company Heat Map Analysis
• 5.4. Company Profiles
  • 5.4.1. DexCom, Inc.
    • 5.4.1.1. Participant's Overview
    • 5.4.1.2. Financial Performance
    • 5.4.1.3. Product Benchmarking
    • 5.4.1.4. Recent Developments/ Strategic Initiatives
  • 5.4.2. Abbott
    • 5.4.2.1. Participant's Overview
    • 5.4.2.2. Financial Performance
    • 5.4.2.3. Product Benchmarking
    • 5.4.2.4. Recent Developments/ Strategic Initiatives

List of Tables

• Table 1 List of secondary sources
• Table 2 List of abbreviations
• Table 3 U.S. Over-the-Counter (OTC) glucose biosensors market by end use, 2018 - 2030 (USD Million)
• Table 4 Participant's overview
• Table 5 Financial performance
• Table 6 Key companies undergoing expansions
• Table 7 Key companies undergoing acquisitions
• Table 8 Key companies undergoing collaborations
• Table 9 Key companies launching new products
• Table 10 Key companies undergoing partnerships
• Table 11 Key companies undertaking other strategies

List of Figures

• Fig. 1 Market research process
• Fig. 2 Data triangulation techniques
• Fig. 3 Primary research pattern
• Fig. 4 Market research approaches
• Fig. 5 Value-chain-based sizing & forecasting
• Fig. 6 QFD modeling for market share assessment
• Fig. 7 Market formulation & validation
• Fig. 8 Market summary, 2024 (USD Million)
• Fig. 9 Market segmentation & scope
• Fig. 10 Market driver impact
• Fig. 11 Market restraint impact
• Fig. 12 Porter's analysis
• Fig. 13 SWOT analysis
• Fig. 14 U.S. Over-the-Counter (OTC) glucose biosensors market: End use outlook and key takeaways
• Fig. 15 U.S. Over-the-Counter (OTC) glucose biosensors market: End use movement analysis
• Fig. 16 Healthcare Professional Offices (HCPs) market, 2018 - 2030 (USD Million)
• Fig. 17 Specialty clinics market, 2018 - 2030 (USD Million)
• Fig. 18 Homecare market, 2018 - 2030 (USD Million)
• Fig. 19 Heat map analysis
• Fig. 20 Market participant categorization
• Fig. 21 U.S. Over-the-Counter (OTC) glucose biosensors market share analysis, 2024
• Fig. 22 Strategy framework